Protara Therapeutics, Inc. (TARA)
Automate Your Wheel Strategy on TARA
With Tiblio's Option Bot, you can configure your own wheel strategy including TARA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TARA
- Rev/Share 0.0
- Book/Share 3.8932
- PB 0.8476
- Debt/Equity 0.0267
- CurrentRatio 18.0296
- ROIC -0.3161
- MktCap 127320270.0
- FreeCF/Share -0.9887
- PFCF -3.1633
- PE -2.958
- Debt/Assets 0.0251
- DivYield 0
- ROE -0.3637
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TARA | Scotiabank | -- | Sector Outperform | -- | $12 | April 16, 2025 |
| Initiation | TARA | Cantor Fitzgerald | -- | Overweight | -- | -- | March 14, 2025 |
News
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
Published: April 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company's investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients with carcinoma in situ, or CIS (± Ta/T1), who are Bacillus Calmette-Guérin (BCG)-Unresponsive or BCG-Naïve. The results will be featured today during an interactive poster session at the American Urological Association 2025 Annual Meeting in Las Vegas.
Read More
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Protara Therapeutics (TARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 9:50 am ET in Boston. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.protaratx.com.
Read More
About Protara Therapeutics, Inc. (TARA)
- IPO Date 2014-10-22
- Website https://www.protaratx.com
- Industry Biotechnology
- CEO Mr. Jesse Shefferman
- Employees 28